| 臺大學術典藏 |
2022-09-15T01:09:51Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chia-Chi Lin; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:51Z |
Down-regulated expression of RhoA in human conventional renal cell carcinoma
|
Pu Y.-S.; Wang C.-W.; Liu G.-Y.; Kuo Y.-Z.; Huang C.-Y.; Kang W.-Y.; Shun C.-T.; Chia-Chi Lin; Wu W.-J.; Hour T.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:51Z |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
|
Hsu F.-M.; Chia-Chi Lin; Lee J.-M.; Chang Y.-L.; Hsu C.-H.; Tsai Y.-C.; Lee Y.-C.; Cheng J.C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:52Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Chia-Chi Lin; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:52Z |
Systemic therapy for metastatic urothelial carcinoma
|
Chia-Chi Lin; Hsu C.-H.; Pu Y.-S.; Vogelzang N.J. |
| 臺大學術典藏 |
2022-09-15T01:09:53Z |
Novel targeted therapies for advanced esophageal cancer
|
Chia-Chi Lin; Papadopoulos K.P. |
| 臺大學術典藏 |
2022-09-15T01:09:53Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Chia-Chi Lin; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:53Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Chia-Chi Lin; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Chia-Chi Lin; Hsu C.; Hsu C.-H.; Hsu W.-L.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:55Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Chia-Chi Lin; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; Yeh K.-H.; Yang C.-H.; Lin J.-T.; Cheng A.-L.; Lee Y.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:55Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:56Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:56Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:56Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Chia-Chi Lin; Hsu C.-H.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:57Z |
Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer
|
Hour T.-C.; Pu Y.-S.; Chia-Chi Lin; Huang S.-W.; Chen J.; Chiu A.W.; Chen C.-J.; Huang C.-Y. |
| 臺大學術典藏 |
2022-09-15T01:09:57Z |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells
|
Pu Y.-S.; Hsieh M.-W.; Wang C.-W.; Liu G.-Y.; Huang C.-Y.; Chia-Chi Lin; Guan J.-Y.; Lin S.-R.; Hour T.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:58Z |
Changing trends of prostate cancer in Asia
|
Pu Y.-S.; Chiang H.-S.; Chia-Chi Lin; Huang C.-Y.; Huang K.-H.; Chen J. |
| 臺大學術典藏 |
2022-09-15T01:09:58Z |
Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide
|
Hour T.-C.; Huang C.-Y.; Chia-Chi Lin; Chen J.; Guan J.-Y.; Lee J.-M.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:59Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Chia-Chi Lin; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:59Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Chia-Chi Lin; Hsu C.-H.; Chen J.; Tsai T.-C.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:12:20Z |
Ventilatory Support for Chronic Respiratory Failure
|
SHIH-CHI KU; CHONG-JEN YU |
| 臺大學術典藏 |
2022-09-15T01:22:53Z |
Postobstructive Pulmonary Edema after Nonlethal Suicidal Hanging
|
Kuo, Jerry Shu-Hung; SHENG-YUAN RUAN; Huang, Chun-Ta; Chen, Wei-Ting |
| 臺大學術典藏 |
2022-09-15T01:23:59Z |
Prevalence of Vitamin D Deficiency and Associated Factors in Critically Ill Patients: A Multicenter Observational Study
|
Chen, Kuo-Wei; Chen, Chung-Wei; Yuan, Kuo-Ching; Wang, I-Ting; Hung, Fang-Ming; Wang, An-Yi; Wang, Yin-Chin; Kuo, Yu-Ting; Lin, Yi-Che; Shih, Ming-Chieh; Kung, Yu-Chung; SHENG-YUAN RUAN; Chiu, Ching-Tang; ANNE CHAO; Han, Yin-Yi; Kuo, Li-Kuo; Yeh, Yu-Chang |
